Bank of New York Mellon Corp Acquires 48,549 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Bank of New York Mellon Corp lifted its stake in Aura Biosciences, Inc. (NASDAQ:AURA) by 51.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 143,027 shares of the company’s stock after acquiring an additional 48,549 shares during the period. Bank of New York Mellon Corp owned approximately 0.29% of Aura Biosciences worth $1,081,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. American International Group Inc. boosted its stake in Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares during the period. Virtu Financial LLC bought a new position in shares of Aura Biosciences in the first quarter valued at approximately $144,000. Trexquant Investment LP grew its stake in Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock valued at $154,000 after acquiring an additional 6,809 shares in the last quarter. TBH Global Asset Management LLC increased its holdings in Aura Biosciences by 82.3% during the 4th quarter. TBH Global Asset Management LLC now owns 60,322 shares of the company’s stock worth $534,000 after acquiring an additional 27,225 shares during the period. Finally, Levin Capital Strategies L.P. lifted its stake in Aura Biosciences by 11.2% in the 1st quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock worth $873,000 after purchasing an additional 11,200 shares in the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AURA shares. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. JMP Securities raised their price target on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of Aura Biosciences in a report on Friday, September 13th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $21.67.

Aura Biosciences Stock Performance

NASDAQ AURA opened at $9.57 on Friday. The company has a market capitalization of $474.13 million, a P/E ratio of -5.15 and a beta of 0.35. Aura Biosciences, Inc. has a 52-week low of $5.99 and a 52-week high of $12.35. The company has a fifty day moving average of $8.71 and a 200-day moving average of $7.90.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.04. As a group, analysts forecast that Aura Biosciences, Inc. will post -1.7 EPS for the current fiscal year.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.